Overall Management > Evaluations and Comparisons


Cancer Invest 2000;18(6):510-5 (Retrospective Study)


Abstract

A retrospective analysis of postradiation chemotherapy in 133 patients with glioblastoma multiforme

Reni M, Cozzarini C, Ferreri AJ, Ceresoli GL, Galli L, Bianchi A, Villa E

Department of Radiochemotherapy, San Raffaele H Scientific Institute, Milan, Italy

The impact on survival of postradiation nitrosourea-containing chemotherapy (CHT) in patients with glioblastoma multiforme (GM) was analyzed retrospectively in 133 patients who completed the planned radiotherapy out of 173 observed cases. Thirty-five patients were < 50 years old, 89 were males, 20 had performance status (PS) < 70 and 72 > or = 70.
Surgery was followed by radiotherapy in all cases (50-60 Gy in 95 patients, 61-70 Gy in 38 patients).
At the end of radiotherapy, 43 patients received CHT, whereas 90 patients did not receive further therapy.
At univariate analysis, age < 50 years, feminine gender, subtotal or total resection, radiotherapy doses > 60 Gy, and CHT had an independent prognostic value.
Our results suggest that chemotherapy improves 2-year survival rates from 12% to 28% in GM.
The sequence of treatment, new drugs, and combinations should be further explored.

PMID: 10923098 [PubMed - indexed for MEDLINE]

Source: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10923098&dopt=Abstract


 

HOME | Detection | Diagnosis | Epidemiology | Etiology & Pathogenesis | Integrative Medicine | Overall Mngt & Case Reports | Prevention | Prognosis | Psychosocial Aspects | Treatment 
About BrainLife
| BL Newsletter |
Children's Corner | E-mail Alerts | Journals | Patients & Caregivers | Search | Stem Cells | WHO Classification | SITEMAP